The University of Arizona College of Medicine-Phoenix, Phoenix, AZ
Tony Duong , Jue Wang
Background: Spinal cord compression (SCC) from prostatic cancer is an oncologic emergency with significant negative impact on morbidity and survival. However, the molecular mechanisms involved in spinal metastases remains largely unclear. The aim of this study was to evaluate the histopathology, molecular profiles, and outcome in these patients. Methods: Twenty patients with magnetic resonance imaging-confirmed metastatic SCC from prostate cancer were identified at Dignity health Cancer Institute. Pathology slides were reviewed and the molecular analysis of 324 cancer-related genes was performed on tumor specimens using targeted next-generation sequencing. Characteristics including age, Gleason score, SCC anatomical site, time to diagnosis of SCC, gene alterations, number of lines of treatment and clinical outcome were analyzed. Results: At the time of diagnosis of SCC, the median age at diagnosis of SCC was 60.5 years old (range=50-76). The median PSA value was 626 ng/ml, 100% of patients have a Gleason score above 7, 30% of patients had visceral metastases. The thoracic spine affecting (15/20) patients is the most common site of SCC. Seventeen patients (75%) were initially treated with surgery combined with radiation therapy (RT), whereas 3 (15%) were managed with RT alone. At the time of this study, 11 patients remain alive (55%), median overall survival (OS) is 20 months, 18 months in treatment naive and 22 months in hormone refractory patients. Molecular analysis revealed gene mutations in all (100%) tumors, The most common gene alterations were PTEN (16%), followed by AR alterations AR (13%), TP53 (11%), TMPRSS2-ERG (8 %), BRCA1/2(4%), RB1(1%) and ATM (1%). Conclusions: Comprehensive genomic profiling revealed several molecular targets in patients with metastatic spinal cord compression from prostate cancer.
Median age at diagnosis of SCC (n=20), years | 60.5 (range 50-76) |
---|---|
Median PSA at SCC ng/ml | 626 |
% of pts with Gleason score ≥7 (n=20) | 100% |
% of pts with visceral metastases(n=4) | 20% |
Episodes of cord compression | 23 |
Anatomical Sites C spine, T spine, L spine, Sacral | (Respectively) 7/20, 15/20, 8/20, 1/20 |
% of Pts who received Surgery (n=17) | 85% |
% of pts who received XRT (n=3) | 15% |
Median OS (months) | 20 (range 9-143) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Denis S. Kutilin
2021 Genitourinary Cancers Symposium
First Author: Ryon Graf
2024 ASCO Genitourinary Cancers Symposium
First Author: Mohammad Arfat Ganiyani
2018 ASCO Annual Meeting
First Author: Arie Carneiro